Shares in Pulmatrix (NSDQ:PULM) jumped more than 8% today on rumors that the company’s collaboration partner Mylan (NSDQ:MYL) may be interested in a takeover bid. In 2015, the 2 companies inked an ex-U.S. development deal for PUR0200, Pulmatrix’s investigational bronchodilator for the treatment of chronic obstructive pulmonary disease. Mylan had an option on the rights […]
Respiratory
Cohero Health oversubscribes Series A for connected respiratory tech
Cohero Health said today that it oversubscribed its $9 million Series A round with investments from Samsung Next and Omron Healthcare The latest contributions will be used to support commercialization of hardware and software for its BreatheSmart connected respiratory disease management platform, the N.Y.-based company said. Get the full story at our sister site, Drug Delivery Business News.
Glenmark wins FDA nod for Phase II study of nebulized tiotropium bromide
Glenmark Pharmaceuticals said today that the FDA approved its Investigational New Drug application for a Phase II study of its nebulized tiotropium bromide. The Mahwah, N.J.-based company plans to enroll 155 patients with mild to moderate chronic obstructive pulmonary disease and evaluate its GSP 304 formulation as a daily maintenance treatment for bronchospasm. Get the full story […]
Demand for EpiPen alternatives jumps as states consider access legislation
Prescriptions for EpiPen alternatives such as Kaléo Inc.‘s Auvi-Q device have quadrupled since the beginning of this year, according to data from the Athenahealth Network. The demand for cheaper alternative devices is likely driven by revelations that Mylan (NSDQ:MYL) hiked the price of its EpiPen emergency allergy injector by 500% since it acquired the device in 2007. Generic […]
Philips Respironics recalls select V60 ventilators over software shut down issues
Royal Philips (NYSE:PHG) Respironics business is recalling a select number of its V60 respiratory ventilators with its version 2.20 software over issues with the software causing the blower motor to stall and the unit to shut down, according to a recall notice released this week. The recall affects all V60 ventilators manufactured between Aug. 17, 2016 […]
Study: Patient error cuts dose in half for inhalers
Researchers from Rice University and Baylor College of Medicine have identified patient errors that cause inhaler users to get about half as much medicine as they should from each dose. The team said that clinicians have known for years that patients don’t use their inhalers as prescribed, but inhaler-dosing studies tend to focus on the rare cases […]
Mylan posts Street-beating Q4 earnings
Shares in Mylan (NSDQ:MYL) rose today after the EpiPen-maker met expectations on Wall Street with its 4th quarter results. The Canonsburg, Pa.-based company posted profits of $417.5 million, or $1.57 per share, on sales of $3.27 billion for the 3 months ended Dec. 31, for bottom-line growth of 114.5% on sales growth of 31.3% compared with the same […]
GlaxoSmithKline, Innoviva tout data for Relvar Ellipta inhaled drug combo
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) touted data today from a non-inferiority lung function study evaluating its inhaled, once-daily corticosteroid/long-acting beta2 agonist combination therapy in patients with asthma. The study showed that patients with well-controlled asthma could switch from the twice-daily Seretide Accuhaler to the companies’ once-daily Relvar Ellipta therapy without compromising lung function. Get the full story […]
ALung raises $2.6m
Artificial lung-like device developer ALung Technologies raised $2.6 million in a new round of debt and options financing, according to an SEC filing posted this week. The Pittsburgh, Penn.-based company is developing the Hemolung device, an extracorporeal carbon dioxide removal system that works by removing carbon dioxide and delivering oxygen directly to a patient’s blood via […]
Actelion reports income, revenue growth in FY2016
(Reuters) – Swiss drugmaker Actelion‘s 2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension (PAH), it said on Tuesday. Core net income rose to 881 million Swiss francs ($877.8 million) from 693 million francs in the previous year, the company said in a statement. […]
Acorda’s inhaled Parkinson’s drug meets primary endpoint in Phase III trial
Acorda Therapeutics (NSDQ:ACOR) said today that the phase III clinical trial evaluating its inhaled formulation of Parkinson’s drug levodopa met its primary endpoint. The drug was studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms. The randomized phase III trial enrolled 339 patients to evaluate the efficacy […]